PHOTO
Dubai: The Ministry of Health and Prevention, MoHAP, has recently signed a memorandum of understanding (MoU) with Bayer Middle East and Axios Health Education Services to provide a one-year medication for MS patients, patients with Pulmonary arterial hypertension (PAH), and patients with chronic thromboembolic pulmonary hypertension (CTEPH), whose medical insurance doesn’t cover the total cost of treatment.
The MoU is part of ‘Da’m’ initiative (Support) launched by MoHAP is 2018.
The agreement was signed at MoHAP headquarters by HE Dr. Amin Hussein Al Amiri, the Assistant Undersecretary of the Ministry of Health and Prevention’s Public Health Policy and Licenses, Henrik Wulff, Managing Director, Bayer Middle East, and Anas Al-Safarini, Executive Director for the Middle East and North Africa, Axios Health Education Services.
Supporting Needy Patients
Dr. Ruqaya Al Bastaki pointed to the importance of renewing the initiative for the second consecutive year, as part of MoHAP’s keenness on mitigating patient’s suffering, especially whose insurance is not covering the total cost of treatment and improve their commitment to the prescribed treatment plan.
The MoU also covers non-insured patients or those with partial insurance coverage.
Bolstering MoHAP’s Efforts
Henrik Wulff, Managing Director, Bayer Middle East, emphasized the company’s keenness on bolstering MoHAP’s efforts in providing MS patients, patients with Pulmonary arterial hypertension (PAH), and patients with chronic thromboembolic pulmonary hypertension (CTEPH) to ensure their adherence to treatment plans.
Facilitating Progress of the Program
Anas Al-Safarini, Executive Director for the Middle East and North Africa, Axios Health Education Services highlighted the importance of renewing the agreement, stressing Axios’s commitment to coordinate with charities and program partners to ensure the seamless progress of the program, in addition to managing patient’s treatment journey through the constant communication to ensure that they regularly receive the medication according to their treatment plan.
-Ends –
For more information, please contact:
1605 230 04
1614 230 04
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
